{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-279091","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.399311+00:00","generated_at":"2026-05-16T20:17:02.427541+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics Q3 cash $225.7M; UK/EU approval for FT819; first SSc patient treated","bullets":["Cash, cash equivalents & investments $225.7M; projected runway through year-end 2027.","Total revenue $1.7M from Ono collaboration; operating expenses $36.5M incl. $4.9M SBC.","Received UK MHRA and EU EMA authorization to activate ex-US sites for FT819 in autoimmune disease.","First systemic sclerosis patient treated in Phase 1 with fludarabine-free conditioning; no notable AEs.","First patient (stage IV CRC) treated with FT836 MICA/B-targeted CAR T with no conditioning chemotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-279091","json":"https://secwatch.observer/filing/0001193125-25-279091.json","markdown":"https://secwatch.observer/filing/0001193125-25-279091.md","text":"https://secwatch.observer/filing/0001193125-25-279091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/0001193125-25-279091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/fate-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:17:02.427541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}